Lingabrique 

Oro-dispersible Tablets 
composition 
Each orodispersible tablet contains 90 mg ticagrelor 

Therapeutic indications 
Lingabrique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention 
of atherothrombotic events in adult patients with - acute coronary syndromes (ACS) or 

- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event .